1.
Hoffman, R.M. and Erbe, R.W.
High in vivo rates of
methionine biosynthesis in transformed human and malignant rat cells auxotrophic
for methionine. Proc. Natl. Acad.
Sci. USA 73, 1523-1527, 1976.
2.
Hoffman, R.M., Jacobsen, S.J., and
Erbe, R.W. Reversion to methionine
independence by malignant rat and SV40-transformed human fibroblasts. Biochem. Biophys. Res. Commun. 82, 228-234, 1978.
3.
Hoffman, R.M., Jacobsen, S.J., and
Erbe, R.W. Reversion to methionine
independence in simian virus
40-transformed human and malignant rat fibroblasts is associated with altered
ploidy and altered properties of transformation. Proc. Natl. Acad. Sci. USA 76,
1313-1317, 1979.
4.
Jacobsen, S.J., Hoffman, R.M., and
Erbe, R.W. Regulation of methionine
adenosyltransferase in normal diploid and SV40-transformed human fibroblasts.
J. Natl. Cancer Inst. 65,
1237-1244, 1980.
5.
Hoffman, R.M., and Jacobsen, S.J.
Reversible growth arrest in simian virus 40-transformed human
fibroblasts. Proc. Natl. Acad. Sci. USA 77,
7306-7310, 1980.
6.
Diala, E.S., Plent, M.M., Coalson, D.W.
and Hoffman, R.M. DNA methylation
in normal and SV40-transformed human fibroblasts.
Biochem. Biophys. Res. Commun. 102,
1379-1384, 1981.
7.
Coalson, D.W., Mecham, J.O., Stern,
P.H. and Hoffman, R.M. Reduced
availability of endogenously synthesized methionine for S-adenosylmethionine
formation in methionine dependent cancer cells.
Proc. Natl. Acad. Sci. USA 79,
4248-4251, 1982.
8.
Diala, E.S. and Hoffman, R.M.
Hypomethylation of HeLa cell DNA and the absence of 5-methylcytosine in
SV40 and adenovirus (type 2) DNA: analysis by HPLC.
Biochem. Biophys. Res. Commun. 107,
19-26, 1982.
9.
Hoffman, R.M.
Methionine dependence in cancer cells – A review.
In Vitro 18,
421-428, 1982.
10.
Diala, E.S. and Hoffman, R.M. DNA
methylation levels in normal and chemically transformed mouse 3T3 cells.
Biochem. Biophys. Res. Commun. 104,
1489-1494, 1982.
11.
Diala, E.S., Cheah, M.S.C., Rowitch,
D., and Hoffman, R.M. Extent of DNA
methylation in human tumor cells. J. Natl. Cancer Inst. 71, 755-764, 1983.[PDF]
12.
Mecham, J.O., Rowitch, D., Wallace,
C.D., Stern, P.H. and Hoffman, R.M. The
metabolic defect of methionine dependence occurs frequently in human tumor cell
lines. Biochem. Biophys. Res.
Commun. 117, 429-434, 1983.
13.
Oden, K.L., Carson, K., Mecham, J.O.,
Hoffman, R.M. and Clarke, S. S-adenosylmethionine
synthetase in cultured normal and oncogenically-transformed human and rat cells.
Biochem. Biophys. Acta 870,
270-277, 1983.[PDF]
14.
Stern, P.H., Mecham, J.O., Wallace,
C.D. and Hoffman, R.M. Reduced
free-methionine in methionine-dependent SV40-transformed human fibroblasts
synthesizing apparently normal amounts of methionine.
J. Cell Physiol. 117, 9-14,
1983.[PDF]
15.
Cheah, M.S.C., Wallace, C.D., and
Hoffman, R.M. Hypomethylation of
DNA in human cancer cells: a site-specific change in the c-myc oncogene. J. Natl.
Cancer Inst. 73, 1057-1065, 1984.
16.
Hoffman, R.M.
Altered methionine metabolism, DNA methylation and oncogene expression in
carcinogenesis: a review and synthesis. Biochem.
Biophys. Acta, Reviews on Cancer 738, 49-87, 1984.[PDF]
17.
Stern, P.H. and Hoffman, R.M.
Elevated overall rates of transmethylation in cell lines from diverse
human tumors. In Vitro – Rapid Commun. in Cell Biology 20, 663-670, 1984.
18.
Stern, P.H., Wallace, C.D., and
Hoffman, R.M. Altered methionine
metabolism occurs in all members of a set of diverse human tumor cell lines.
J. Cell Physiol. 119, 29-34, 1984.
19.
Hoffman, R.M.
Altered methionine metabolism and transmethylation in cancer.
Anticancer Research 5, 1-30, 1985.
20.
Hoffman, R.M. and Stern, P.H.
Cancer, methionine and transmethylation.
In Biological Methylation and Drug
Design, Borchardt, R.T., Creveling, C.R., and Ueland, P.M., eds., Clifton,
New Jersey, The Human Press Inc., 215-225, 1986.
21.
Stern, P.H. and Hoffman, R.M.
Enhanced in vitro selective
toxicity of chemotherapeutic agents for human cancer cells based on a metabolic
defect. J. Natl. Cancer Inst. 76,
629-639, 1986.
22.
Hoffman, R.M.
Altered methionine metabolism and unbalanced methylation: a possible
basis for the dynamic phenotype of cancer.
Absorption and Utilization of Amino Acids, M. Friedman, ed., CRC
Press, Boca Raton, Florida, 1-7, 1989.
23.
Hoffman, R.M.
Unbalanced transmethylation and the perturbation of the differentiated
state leading to cancer. BioEssays 12,
163-166, 1990.
24.
Guo, H.Y., Herrera, H., Groce, A., and
Hoffman, R.M. Expression of the
biochemical defect of methionine dependence in fresh patient tumors in primary
histoculture. Cancer Res. 53,
2479-2483, 1993.
25.
Guo, H.Y., Herrera, H., and Hoffman,
R.M. Unchecked DNA synthesis and
blocked cell division induced by methionine deprivation in a human prostate
cancer cell line. In Vitro Cell.
Dev. Biol. 29A, 359-361, 1993.
26.
Lishko, V.K., Lishko, O.V., and
Hoffman, R.M. The preparation of
endotoxin-free l-methionine-a-deamino-g-mercaptomethane-lyase
(l-methioninase) from Pseudomonas
putida. Protein Expression and
Purification 4, 529-533, 1993.
27.
Lishko, V.K., Lishko, O.V., and
Hoffman, R.M. Depletion of serum
methionine by methioninase in mice. Anticancer Research 13,
1465-1468, 1993.
28.
Guo, H., Lishko, V., Herrera, H.,
Groce, A., Kubota, T., and Hoffman, R.M. Therapeutic
tumor-specific cell-cycle block induced by methionine starvation in
vivo. Cancer Res. 53, 5676-5679, 1993.
29.
Hoshiya, Y., Guo, H., Kubota, T.,
Inada, T., Asenuma, F., Yamada, Y., Koh, J., Kitajima, M., and Hoffman, R.M.
Human tumors are methionine dependent in
vivo. Anticancer Research 15, 717-718, 1995.
30.
Goseki, N., Yamazaki, S., Shimojyu, K.,
Kando, F., Maruyama, M., Endo, M., Koike, M., and Takahashi, H. Synergistic
effect of methionine-depleting total parenteral nutrition with 5-fluorouracil on
human gastric cancer: A randomized, prospective clinical trial.
Jpn. J. Cancer Res. 86, 484-489, 1995.
31.
Tan, Y., Xu, M., Guo, H., Sun, X.,
Kubota, T., and Hoffman, R.M. Anticancer
efficacy of methioninase in vivo.
Anticancer Research 16, 3931-3936,
1996.
32.
Tan, Y., Zavala Sr., J., Xu, M., Zavala
Jr., J., and Hoffman, R.M. Serum
methionine depletion without side effects by methioninase in metastatic breast
cancer patients. Anticancer
Research 16, 3937-3942, 1996.
33.
Guo, H., Tan, Y., Kubota, T., Moossa,
A.R., and Hoffman, R.M. Methionine
depletion modulates the antitumor and antimetastatic efficacy of ethionine.
Anticancer Research 16, 2719-2724, 1996.
34.
Hoshiya, Y., Kubota, T., Matsuzaki, S.,
Kitajima, M., and Hoffman, R.M. Methionine
starvation modulates the efficacy of cisplatin on human breast cancer in nude
mice. Anticancer Research 16,
3515-3518, 1996.[PDF]
35.
Goseki, N., et al. Evaluation of the survival time of A0-90 clinical trial for
progressive or recurrent gastric cancer. J.
Jpn. Soc. for Cancer Ther., Vol. XXXI, No. 8, p. 610 (172), 20 September 1996.
36.
Tan, Y., Xu, M., Tan, X-Z., Tan, X-Y.,
Wang., X., Saikawa, S., Nagahama, T., Sun, X., Lenz, M., and Hoffman, R.M.
Overexpression and large-scale production of recombinant l-methionine-a-deamino-g-
mercaptomethane-lyase for novel anticancer therapy. Protein Expression and Purification 9, 233-245, 1997. [PDF]
37.
Hoffman, R.M.
Recombinant Methioninase. Drugs
of the Future 22, 130-134, 1997.
38.
Hoffman, R.M.
Methioninase: A therapeutic for diseases related to altered methionine
metabolism and transmethylation: cancer, heart disease, obesity, aging, and
Parkinson’s disease. Human Cell 10,
69-80, 1997.
39.
Tan, Y., Zavala, J. Sr., Han, Q., Xu,
M., Sun, X., Tan, X-H., Tan, X., Magana, R., Geller, J., and Hoffman, R.M.
Recombinant methioninase infusion reduces the biochemical endpoint of serum
methionine with minimal toxicity in high-stage cancer patients. Anticancer Research 17,
3857-3860, 1997.
40.
Hoffman, R.M. Is methioninase useful
for the prevention of hyperhomocysteinemia-associated cardiovascular disease?
Homocysteine Metabolism: From Basic Science to Clinical Medicine. Ed: I. Graham,
H. Refsum, I.H. Rosenberg, P.M. Ueland, Kluwer Academic Publishers,
Massachusetts, pp. 155-156, 1997.
41.
Kokkinakis, D.M., Schold, S.C. Jr.,
Hori, H., and Nobori, T. Effect of
long-term depletion of plasma methionine on the growth and survival of human
brain tumor xenografts in athymic mice. Nutrition
and Cancer 29, 195-204, 1997.
42.
Kokkinakis, D.M., von Wronski, M.A.,
Vuong, T.H., Brent, T.P., and Schold, S.C. Jr.
Regulation of O6-methylguanine-DNA methyltransferase by methionine in
human tumour cells. British Journal
of Cancer 75, 779-788, 1997.
43.
Hoshiya, T., Kubota, T., Inada, T.,
Kitajima, M., and Hoffman, R.M. Methionine-depletion
modulates the efficacy of 5-fluorouracil on human gastic cancer in nude mice.
Anticancer Research 17,
4371-4376, 1997.
44.
Tan, Y., Sun, X., Xu, M., An, Z., Tan,
X-Z., Tan, X-Y., Han, Q., Miljkovic, D.A., Yang, M., and Hoffman, R.M.
Polyethylene glycol conjugation of recombinant methioninase for cancer therapy.
Protein Expression and Purification 12,
45-52, 1998.
45.
Nagahama, T., Goseki, N., and Endo, M.
Doxorubicin and vincristine with methionine depletion contributed to
survival in the Yoshida sarcoma bearing rats.
Anticancer Research 18, 25-32, 1998.
46.
Yoshioka, T., Wada, T., Uchida, N.,
Maki, H., Yoshida, H., Ide, N., Kasai, H., Hojo, K., Shono, K., Maekawa, R.,
Yagi, S., Hoffman, R.M., and Sugita, K. Anticancer
efficacy in vivo and in
vitro, synergy with 5-fluorouracil, and safety of recombinant methioninase.
Cancer Research 58, 2583-2587, 1998.
47.
Tan, Y., Sun, X., Xu, M., Tan, X-Z.,
Sasson, A., Rashidi, B., Han, Q., Tan,
X-Y., Wang, X., An, Z., Sun, F-X.,
and Hoffman, R.M. Efficacy of
recombinant methioninase in combination with cisplatin on human colon tumors in
nude mice. Clinical Cancer Research
5, 2157-2163, 1999.
48.
Miki, K., Xu, M., An, Z., Wang, X.,
Yang, M., Al-Refaie, W., Sun, X., Baranov, E., Tan, Y., Chishima, T., Shimada,
H., Moossa, A.R., Hoffman, R.M. Survival
efficacy of the combination of the methioninase gene and methioninase in a lung
cancer orthotopic model. Cancer
Gene Therapy 7, 332-338, 2000.
49.
Miki, K., Al-Refaie, W., Xu, M., Jiang,
P., Tan, Y., Bouvet, M., Zhao, M., Gupta, A., Chishima, T., Shimada, H.,
Makuuchi, M., Moossa, A.R., and Hoffman, R.M.
Methioninase gene therapy of human cancer cells is synergistic with
recombinant methioninase treatment. Cancer Research 60, 2696-2702, 2000.
50.
Sridhar, V., Xu, M., Han, Q., Sun, X.,
Tan, Y., Hoffman, R.M., and Prasad, G.S. Crystallization
and preliminary crystallographic characterization of recombinant L-methionine-a-deamino-g-mrcaptomethane
lyase (Methioninase). Acta Cryst., D56,
1665-1667, 2000.[PDF]
51.
Machover, D., Zittoun, J., Broet, P.,
Metzger, G., Orrico, M., Goldschmidt, E., Schilf, A., Tonetti, C., Tan, Y.,
Delmas-Marsalet, B., Luccioni, C., Falissard, B., and Hoffman, R.M. Cytotoxic
synergism of methioninase in combination with 5-fluorouracil and folinic acid.
Biochem. Pharmacology 61, 867-876,
2001.
52.
Kokkinakis, D.M., Hoffman, R.M.,
Frenkel, E.P., Wick, J.B., Han, Q., Xu, M., Tan, Y., Schold, S.C. Synergy between methionine stress and chemotherapy in the
treatment of brain tumor xenografts in athymic mice. Cancer Research 61,
4017-4023, 2001.
53.
Miki, K, Xu, M., Gupta, A., Ba, Y.,
Tan, Y., Al-Refaie, W., Bouvet, M., Makuuchi, M., Moossa, A.R., and Hoffman,
R.M. Methioninase cancer gene
therapy with selenomethionine as suicide prodrug substrate.
Cancer Research 61, 6805-6810,
2001. [PDF]
54. Machover D., Zittoun J., Saffroy R., Broet P., Giraudier S., Magnaldo T., Goldschmidt E., Debuire B., Orrico M., Tan Y., Mishal Z., Chevallier O., Tonetti C., Jouault H., Ulusakaraya A., Tanguy M.-L., Metzger G., Hoffman R.M. Treatment of Cancer Cells with Methioninase Produces DNA Hypomethylation and Increases DNA Synthesis. Cancer Research, 62, 4685-4689, 2002. [PDF]
55. Li, S., Yang, Z., Sun, X., Tan, Y., Yagi, S., and Hoffman, R.M. A simultaneous colorimetric assay of free and protein-coupled polyethylene glycol. Anal. Biochem. 313, 335-337, 2003.[PDF]
56. Yamamoto, N., Gupta, A., Xu, M., Miki, K. Tsujimoto, Y., Tsuchiya, H., Tomita, K., Moossa, A.R., Hoffman, R.M. Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Therapy 10, 445-450. 2003 [PDF]
57. Gupta, A., Miki, K., Xu, M., Yamamoto, N., Moosa, A.R., and Hoffman, R.M. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Research 23, 1181-1188, 2003.[PDF]
58. Hoffman, R.M. PEG-methioninase. In: Advances in Experimental Medicine and Biology: Polymer Drugs in the Clinical Stage, vol. 519, 69-79. Maeda, H., Kabanov, A., Kataoka, K., Okano, T., eds. Dordecht, The Netherlands: Kluwer Academic/Plenum Publishers, 2003.
59. Sun, X., Yang, Z., Li,S., Tan, Y., Zhang, N., Wang, X., Yagi, S., Yoshioka, T., Takimoto, A., Mitsushima, K., Suginaka, A., Frenkel, E.P., and Hoffman, R.M. In vivo efficacy of recombinant methioninase is enchanced by the combination of polyethylene glycol conjugation and pyridoxal 5' phosphate supplementation. Cancer Research, 63, 8377-8383, 2003. [PDF]
60. Takakura, T., Mitsushima, K., Yagi, S., Inagaki, K., Tanaka, H., Esaki, N., Soda, K., Takimoto, A. Assay method for antitumor L-methionine g-lyase: comprehensive kinetic analysis of the complex reaction with L-methionine. Analytical Biochemistry 327, 233-240.2004. [PDF]
61. Yang, Z., Wang, J., Yoshioka, T., Li, B., Lu, Q., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E.P., Hoffman, R.M. A. Pharmacokinetics, Methionine Depletion, and Antigenecity of Recombinant Methioninase in Primates. Clinical Cancer Research 10, 2131-2138, 2004. [PDF]
62. Li, S-K., Yang, Z., Sun, X., Tan, Y., Yagi, S., and Hoffman, R.M. A. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation. Analytical Biochemistry, 330, 264-271, 2004.[PDF]
63. Yang, Z., Sun, X., Li, S., Tan, Y., Wang, X., Zhang, N., Yagi, S., Takakaura, T., Kobayashi, Y., Takimoto, A., Yoshioka, T., Suginaka, A., Frenkel, E.P., and Hoffman, R.M. Circulating half-life of PEGylated recombinant methioninase holoenzyme is highly dose dependent on cofactor pyridoxal-5'-phosphate. Cancer Research 64, 5775-5778, 2004. [PDF]
64. Yang, Z., Wang, J., Lu, Q., Xu, j., Kobayashi, Y., Takakura, T., Takimoto, A., Yoshioka, T., Lian, C., Chen, C., Zhang, D., Zhang, Y., Li, S., Sun, X., Tan, Y., Yagi, S., Frenkel, E.P., and Hoffman, R.M. PEGylation confers greatly extended half-life and attenuated immunogenecity to recombinant methioninase in primates. Cancer Research 64, 6673-6678, 2004.[PDF]
65. Sun, X., Tan, Y., Yang, Z., Li, S., and Hoffman, R.M. A rapid HPLC method for the measurement of ultra-low plasma methionine concentrations applicable to methionine depletion therapy. AntCancer Research 24, 59-62, 2005.[PDF]
66. Takakura, T., Ito, T., Yagi, S., Notsu, Y., Itakura, T., Nakamura, T., Inagaki, K., Esaki, N., Hoffman, R.M., Takimoto, A. High-level expression and bulk crystallisation of recombinant L-methionine-g-lyase, an anticancer agent. Appl. Microbiol. Biotechnol. 70, 183-192, 2006. DOI: 10.1007/s00253-005-0038-2.[PDF]
67. Takakura, T., Takimoto, A., Notsu, Yoshida, H., Ito, T., Nagatome, H., Ohno, M., Kobayashi, Y., Yoshika, T., Inagaki, K., Yagi, S., Hoffman, R.M., and Esaki, N. Physicochemical and pharmacocinetic characterization og highly potent recombinant L-methionine-g-lyase conjugated with polyethylene glycol as an antitumor agent. Cancer Res. 66, 2807-2814, 2006. [PDF]